Table 3 Clinical trials of drugs targeting ECM stiffness or downstream signals (clinicaltrials.gov)
From: Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer
Target | Drugs | Conditions | NCT number | Phase | Status |
|---|---|---|---|---|---|
TGF-β | Bintrafusp alfa | Uterine Cervical Neoplasms | NCT04246489 | II | Recruiting |
Galunisertib | Metastatic Pancreatic Cancer | NCT02734160 | I | Completed | |
TEW-7197 | Advanced Stage Solid Tumors | NCT02160106 | I | Completed | |
LY2157299 | Hepatocellular Carcinoma | NCT02178358 | II | Completed | |
Halofuginone | Unspecified Adult Solid Tumor, Protocol Specific | NCT00027677 | I | Completed | |
Fresolimumab | Stage IA Non-Small Cell Lung Carcinoma Stage IB Non-Small Cell Lung Carcinoma | NCT02581787 | I/II | Completed | |
Losartan | Glioblastoma Brain Metastases | NCT03951142 | II | Enrolling by invitation | |
FOLFIRNINOX | Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma Metastatic | NCT05077800 | II | Recruiting | |
S-3304 | Solid Tumors | NCT00033215 | I | Completed | |
Collagan | Collagenase | Dupuytren’s Contracture | NCT00004409 | II | Completed |
D-Penicillamine | Head and Neck Cancer Recurrent Cancer | NCT06103617 | II | Recruiting | |
LOX | ATN-224 | Breast Cancer | NCT00674557 | II | Terminated |
PXS-5505 | Myelofibrosis | NCT04676529 | I/II | Active, not recruiting | |
LOX | PXS-5382A | Healthy adults | NCT04183517 | I | Completed |
LOXL2 | Simtuzumab (GS-6624) | Liver Fibrosis Due to NASH | NCT01672879 | II | Terminated |
Epigallocatechin-3-gallate (EGCG) | Idiopathic Pulmonary Fibrosis | NCT03928847 | I | Completed | |
PXS-5505 | Myelofibrosis | NCT04676529 | I/II | Active, not recruiting | |
GB2064 | Myelofibrosis | NCT04679870 | II | Active, not recruiting | |
LOXL2 | PAT-1251 | Myelofibrosis Transformation in Essential Thrombocythemia Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase Primary Myelofibrosis | NCT04054245 | II | Withdrawn |
AGE | Ramipril | Atherosclerosis | NCT01053910 | IV | Completed |
Dapagliflozin | Azheimer disease | NCT03801642 | I/II | Completed | |
CAF | Sonidegib | Locally Advanced Basal Cell Carcinoma | NCT04806646 | II | Recruiting |
Vismodegib | Basal Cell Carcinoma | NCT02639117 | I | Completed | |
Sibrotuzumab | Carcinoma, Non-Small-Cell Lung | NCT02209727 | I | Terminated | |
RO6874281 | Solid Tumor Breast Cancer Cancer of Head and Neck | NCT02627274 | I | Completed | |
68Â Ga-FAPi-46 | Cancer of Unknown Primary Site | NCT05263700 | Not Applicable | Recruiting | |
68Â Ga-FAP-2286 | Solid Tumor | NCT04939610 | I/II | Recruiting | |
PET/CT ([F-18] FAPI-74) | Neoplasms | NCT05442151 | Not Applicable | Recruiting | |
MMP | 18-FDG | Solid Tumor | NCT06719856 | Â | Not yet recruiting |
Doxycycline | Lymphangioleiomyomatosis Tuberous Sclerosis | NCT00989742 | IV | Completed | |
COL-3 | Lymphoma Melanoma Neoplasm Metastasis 1 more | NCT00001683 | I | Completed | |
Prinomastat | Brain and Central Nervous System Tumors | NCT00004200 | II | Completed | |
S-3304 | Solid Tumors | NCT00033215 | I | Completed | |
Marimastat | Lung Cancer | NCT00003011 | III | Completed | |
Prinomastat (AG3340) | Lung Cancer | NCT00004199 | III | Completed | |
Neovastat (AE-941) | Kidney Cancer | NCT00005995 | III | Completed | |
Genistein | Colon Cancer Rectal Cancer Colorectal Cancer | NCT01985763 | I/II | Completed | |
COL-3 | Lymphoma Melanoma Neoplasm Metastasis 1 more | NCT00001683 | I | Completed | |
Tobramycin | Pancreatic Cancer | NCT01693523 | II | Completed | |
Integrin | Abciximab | Acute Myocardial Infarction | NCT00894023 | III | Terminated |
Cilengitide | Glioblastoma | NCT00689221 | III | Completed | |
ATN-161 | Malignant glioma | NCT04177108 | I/II | Completed | |
MEDI-522 | Metastatic mela-noma | NCT00066196 | II | Completed | |
Eptifibatide | Acute Coronary Syndrome | NCT01919723 | II | Completed | |
Tirofiban | Acute Myocardial Infarction | NCT00300833 | IV | Unknown status | |
Natalizumab | Primary Progressive Multiple Sclerosis Secondary Progressive Multiple Sclerosis | NCT01077466 | II | Completed | |
Vedolizumab | Crohn’s Disease | NCT02674308 | IV | Terminated | |
Lifitegrast | Dry Eye Disease | NCT02284516 | III | Completed | |
FAK | Defactinib (VS-6063) | Non Hematologic Cancers | NCT01943292 | I | Completed |
VS-4718 | Non Hematologic Cancers Metastatic Cancer | NCT01849744 | I | Terminated | |
GSK2256098 | Cancer Neoplasms | NCT01938443 | I | Completed | |
SIGX1094R | Advanced Solid Tumors | NCT06739291 | I | Recruiting | |
VS-6766 | NSCLC Low Grade Serous Ovarian Cancer Endometrioid Carcinoma | NCT03875820 | I | Active, not recruiting | |
PF-04554878 | Cancer | NCT00787033 | I | Completed | |
CT-707 | Advanced Pancreatic Cancer | NCT05580445 | I/II | Recruiting | |
PF00562271 | Head and Neck Neoplasm Prostatic Neoplasm Pancreatic Neoplasm | NCT00666926 | I | Completed | |
YAP/TAZ | Verteporfin (VP) | Solid Tumors, Adult Solid Tumor Malignant Pleural Mesothelioma (MPM) 5 more | NCT06381154 | I | Terminated |
IK-930 | Solid Tumors, Adult Solid Tumor Malignant Pleural Mesothelioma (MPM) 5 more | NCT05228015 | I | Terminated | |
VT3989 | Solid Tumor, Adult Mesothelioma | NCT04665206 | I/II | Recruiting | |
SRC | Dasatinib | Malignant Solid Tumour | NCT00388427 | I | Completed |
β-catenin | PRI-724 | Advanced Pancreatic Cancer Metastatic Pancreatic Cancer Pancreatic Adenocarcinoma | NCT01764477 | I | Completed |
ROCK | Fasudil | Cognitive Decline, Mild Alzheimer Disease | NCT06362707 | II | Recruiting |
CD33 | CRISPR/Cas9 Gene Editing | Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT05662904 | I | Not yet recruiting |
DDR1 | DAT-2645 tablet | Solid Cancers BRCA Mutation HRD Cancer | NCT06614751 | I | Not yet recruiting |
Elimusertib (BAY1895344) | Advanced Solid Tumors | NCT04095273 | I | Completed |